drugset
drugset / Trial / NCT07243366

Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis

NCT07243366 ↗

Phase 0 Not yet recruiting 15 enrolled Guangdong ProCapZoom Biosciences Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study is a single-center, prospective, nonrandom, single-arm trial.

Timeline

Start
2025-11-25
Primary completion
2027-06-30
Completion
2027-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CD19-CAR-NK Cells Cell therapy — Intravenous

Indications

myasthenia gravis